Management is transitioning from a historical model of one IPO every 18 months to a target of 3 to 5 launches annually by leveraging AI to remove information inertia.

The firm identifies AI as a 'game changer' that compresses deep due diligence and S-1 preparation timelines from months to weeks through agentic models and expert-led SOPs.

MDB has invested approximately $4 million annually since its IPO to stand up MDB Direct and PatentVest as independent, high-value enterprises ready for monetization.

Performance attribution for the past year reflects a 'tough road' where internal expectations were not met, leading to cost-cutting measures including retracted RSUs and frozen raises.

The strategic rationale for going public was to transform public venture into a scalable asset class, building diversified portfolios rather than single-company investments for retail clients.

Management attributes the stock's decline to a difficult microcap environment characterized by horrific dilution and a slower-than-anticipated ramp-up of the new operating model.

MDB plans to spin out and finance PatentVest as an independent entity before the end of 2025, with a target for a public listing in 2027.

The company is seeking strategic partnerships for MDB Direct to monetize the self-clearing asset and solve the 'distribution gap' required for higher-volume IPO scaling.

Post-spin-out, management expects annual operating expenses to drop to approximately $6 million, creating significant financial leverage for future equity earnings.

The Paulex IPO is targeted for September 2025, timed to coincide with the initiation of clinical trials for its diabetes treatment.

Future scaling is contingent on broadening distribution beyond the current 675 active accounts to avoid over-reliance on a few large investors.

MDB Direct is positioned as a rare self-clearing asset in the microcap space, which management believes holds significant value for firms lacking internal clearing capabilities.

PatentVest has transitioned into an Alternative Business Structure (ABS) law firm to provide attorney-client privilege, a move intended to disrupt the $10 billion to $15 billion U.S. patent prosecution market.

Management explicitly flags 'distribution gap' as their primary concern, noting that the ability to find investors is currently a tighter bottleneck than finding high-quality companies.

The portfolio includes a 'serendipitous' investment in Buda Juice, justified by a global consumer shift toward fresh, non-processed foods and the company's existing profitability.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management believes traditional SaaS models will be 'crushed' by AI because off-the-shelf tools allow firms to build internal solutions without dedicated software developers.

PatentVest reduced patentability analysis time from 45 hours to 1.5 hours using AI agents, shifting the value proposition from data access to 'human-in-the-loop' IP development.

Cue Biopharma is noted as 'struggling' with management and board cohesion, though its underlying technology and partnerships remain viewed as 'massive game-changers.'

HeartBeam is described as having the most sensitive ambulatory ECG available, with management awaiting a strategic partnership to bring the technology to scale.

ClearSign is characterized as being on a 'long commercialization journey' that is becoming more relevant due to increased natural gas usage.

Management expects minimal dilution for eXoZymes because the business model focuses on capital-efficient biomanufacturing rather than expensive clinical trials.

The company is shifting from a service-based partnership model to direct product manufacturing in the NCT and cannabinoid sectors.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.